About YUMAB GmbH

Sponsor retains sole responsibility for content.

YUMAB is a German biotech company that provides the discovery and development of fully human antibodies from world’s largest, natural derived, universal, human antibody libraries (>10e11) and patient specific libraries in combination with powerful in vitro selection technologies. YUMAB’s antibody platform is based on more than 28 years of research and development in recombinant antibody technologi...

YUMAB is a German biotech company that provides the discovery and development of fully human antibodies from world’s largest, natural derived, universal, human antibody libraries (>10e11) and patient specific libraries in combination with powerful in vitro selection technologies. YUMAB’s antibody platform is based on more than 28 years of research and development in recombinant antibody technologies by its founders. With this platform YUMAB generates antibody candidates with natural, close to germ-line sequences for lowest immunogenicity and with pre-designed properties (e.g., interspecies X-reactivity, large epitope coverage or targeted epitopes). The candidates are highly developable into several antibody drug formats like full-length IgGs, Fabs, scFvs, bispecifics, chimeric antigen receptors (CARs), fusion proteins, and antibody drug conjugates (ADCs). YUMAB provides customized solutions from target discovery and production, personalized antibody libraries, optimized antibody discovery strategies (also directly on cells) to close to germline antibody engineering and lead development with high success-rates even to difficult targets like GPCRs. YUMAB offers flexible business models from fee-for-service solutions to collaborative projects. Services are not limited to therapeutic development – it also contains recombinant antibody development for next-generation research and for diagnostic applications.

Contact YUMAB GmbH

Phone Number
+49 531 3804 270

More About YUMAB GmbH

Therapeutic Areas
  • Autoimmune disorders
  • Infectious
  • Metabolic
  • Oncology
Technologies
  • Biologics
  • Diagnostics
  • Drug delivery
  • Vaccines
Company Type
  • Biotechnology – Therapeutics
State of Ownership
  • Private
Sponsorship Group
  • Networker
Go to the profile of Samia Burridge

Samia Burridge

Business Development Manager, Global Sponsorship, Nature Research Group

Go to the profile of Albany A. Cordova Martins

Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature